TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02506465

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Arm
Description: Foley catheter will be placed and immediately removed.
Study: NCT03959553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline
Study: NCT01914588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: * Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits
Study: NCT00809393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: 30 mg/kg
Study: NCT04759573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Vocal Contact
Description: Mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Observation
Description: Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
Study: NCT03758378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
Study: NCT03060889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
Study: NCT01399853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160U /0.5ml EV71 Vaccine
Description: inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160U /0.5ml EV71 Vaccine
Description: inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320U /0.5ml EV71 vaccine
Description: inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320U /0.5ml EV71 vaccine
Description: inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640U /0.5ml EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640U /0.5ml EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (without adjuvant) 640U /0.5ml
Description: inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
Study: NCT02237131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptives cyclic
Description: tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptives cyclic
Description: tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
Study: NCT01399853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (without adjuvant) 640U /0.5ml
Description: inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 28 days interval
Study: NCT01198626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-32729463
Description: 150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
Study: NCT02237131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptives continuous
Description: Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptives continuous
Description: Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
Study: NCT01459081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 10 mg inhaled by mouth, twice daily, for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhaled by mouth, twice daily, for 5 days
Study: NCT01352104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEP-TE
Description: PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses.
Study: NCT00990405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprzole+Amoxicillin+Clarithromycin
Description: Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
Study: NCT01198626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-32729463 (Open-Label)
Description: Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
Study: NCT03470025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: 1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: 1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR.
Study: NCT04883268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expand Your Horizon
Description: Expand Your Horizon is an online programme, comprising three 15min writing exercises delivered over the course of 1 week. In each writing exercise, participants are asked to describe the functions of their body, and why those are personally meaningful to them.
Study: NCT03530358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-aided rehabilitation
Description: VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
Study: NCT02846324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Capsules which contain GBT440 drug substance in Swedish orange

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Capsules which contain GBT440 drug substance in Swedish orange

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Capsules which contain GBT440 drug substance in Swedish orange

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04328766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202005, alone
Description: DWC202005, as a single dose
Study: NCT03945045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subclavian vein approach
Description: Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
Study: NCT03641092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringParenting Intervention
Description: The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Well Child Care
Description: The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site \[when recruited families will be ineligible for CenteringParenting groups that will start in control sites\]. They will receive anticipatory guidance and handouts that are standard for the clinic.
Study: NCT03575897

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of infant body composition
Description: Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of infant body composition
Description: Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
Study: NCT04328766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 + DWC202005
Description: DWP14012 and DWC202005, as a single dose
Study: NCT03945045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal jugular vein approach
Description: internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
Study: NCT01835496

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: single 1500 mg dose of Ferriprox
Description: A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
Study: NCT04328766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 + DWC202005, after multiple doses of DWP14012
Description: DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
Study: NCT03873025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and CXD101
Description: Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
Study: NCT04356612

Intervention type: OTHER
Intervention: Chart Review
Description: This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
Study: NCT04666324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Solution
Description: Oral daily treatment for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multilac Baby
Description: Oral daily treatment for four weeks
Study: NCT03141086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LML134
Description: LML134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LML134
Description: LML134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT02273232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise
Description: constructed extra excessive for peripheral vascular diastase patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise
Description: constructed extra excessive for peripheral vascular diastase patients
Study: NCT03437642

Intervention type: BEHAVIORAL
Intervention: Short Term Psychotherapy
Description: Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
Study: NCT02029664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual distortion increment based on the gait pattern
Study: NCT01813825

Intervention type: OTHER
Intervention: Registry
Study: NCT02457507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 2 tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets
Study: NCT00128193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tuberculin, Purified Protein Derivative
Description: A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLSA-LAM
Description: Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
Study: NCT00810862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimecrolimus active cream
Description: Pimecrolimus 1% cream apply to affected study area twice daily for 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo base cream
Description: apply to affected study area twice daily for 21 days
Study: NCT02927834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 day Prednisone
Description: 6 day prednisone burst

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: Antibiotic augmentin for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: Antibiotic augmentin for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: Antibiotic augmentin for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21 day Prednisone
Description: 21 day prednisone burst
Study: NCT02740179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 50mg by mouth twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: Counseling regarding diet and healthy activity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Modification
Description: Counseling regarding diet and healthy activity
Study: NCT00328679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: in vitro and in vivo allergy testing
Description: Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
Study: NCT00692952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a novel Benzalkonium Chloride (BZK) contraceptive gel
Description: insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LELEMI® contraceptive gel containing 50mg nonoxynol-9
Description: insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
Study: NCT04403516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intracanalicular Insert, 0.4mg
Description: To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1%
Description: To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
Study: NCT00984516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal Placebo, 100μl administered once prior to wounding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Study: NCT03766217

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells associated with biomaterials
Description: Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest autogenous bone graft
Description: Autogenous bone will be obtained from iliac crest.
Study: NCT04425122

Intervention type: DIAGNOSTIC_TEST
Intervention: Upper endoscopy
Description: Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa

Intervention type: DIAGNOSTIC_TEST
Intervention: Upper endoscopy
Description: Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
Study: NCT04489186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable device
Description: Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
Study: NCT03783988

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: DHEA and TRIAC
Description: The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
Study: NCT04309526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCO-48 Fumarate
Description: NCO-48 Fumarate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo